Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production

References

• Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010; 95(1):135-43; PMID:19773256; http://dx.doi.org/10.3324/haematol.2008.001628
   PubMed Web of Science ®Google Scholar
• Illidge T, Klein C, Sehn LH, Davies A, Salles G, Cartron G. Obinutuzumab in hematologic malignancies: lessons learned to date. Cancer Treat Rev 2015; 41(9):784-92; PMID:26190254; http://dx.doi.org/10.1016/j.ctrv.2015.07.003
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370(12):1101-10; PMID:24401022; http://dx.doi.org/10.1056/NEJMoa1313984
   PubMed Web of Science ®Google Scholar
• Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016; 17(8):1081-93; PMID:27345636; http://dx.doi.org/10.1016/S1470-2045(16)30097-3
   PubMed Web of Science ®Google Scholar
• Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner KP, Umaña P, Niederfellner G. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 2013; 5(1):22-33; PMID:23211638; http://dx.doi.org/10.4161/mabs.22771
   PubMed Web of Science ®Google Scholar
• Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186(6):3762-9; PMID:21296976; http://dx.doi.org/10.4049/jimmunol.1000303
   PubMed Web of Science ®Google Scholar
• Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115(22):4393-402; PMID:20194898; http://dx.doi.org/10.1182/blood-2009-06-225979
   PubMed Web of Science ®Google Scholar
• Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol 2014; 192(5):2252-60; PMID:24489098; http://dx.doi.org/10.4049/jimmunol.1301249
   PubMed Web of Science ®Google Scholar
• Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013; 122(20):3482-91; PMID:24106207; http://dx.doi.org/10.1182/blood-2013-05-504043
   PubMed Web of Science ®Google Scholar
• Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117(17):4519-29; PMID:21378274; http://dx.doi.org/10.1182/blood-2010-07-296913
   PubMed Web of Science ®Google Scholar
• Gagez AL, Cartron G. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol 2014; 26(5):484-91; PMID:25014645; http://dx.doi.org/10.1097/CCO.0000000000000107
   PubMed Web of Science ®Google Scholar
• Montalvao F, Garcia Z, Celli S, Breart B, Deguine J, Van Rooijen N, Bousso P. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest 2013; 123(12):5098-103; PMID:24177426; http://dx.doi.org/10.1172/JCI70972
   PubMed Web of Science ®Google Scholar
• Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199(12):1659-69; PMID:15210744; http://dx.doi.org/10.1084/jem.20040119
   PubMed Web of Science ®Google Scholar
• Grandjean CL, Montalvao F, Celli S, Michonneau D, Breart B, Garcia Z, Perro M, Freytag O, Gerdes CA, Bousso P. Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies. Sci Rep 2016; 6:34382; PMID:27698437; http://dx.doi.org/10.1038/srep34382
   PubMed Web of Science ®Google Scholar
• Deligne C, Metidji A, Fridman WH, Teillaud JL. Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia 2015; 29(4):947-57; PMID:25231744; http://dx.doi.org/10.1038/leu.2014.275
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia 2017; PMID:27890931; http://dx.doi.org/10.1038/leu.2016.352
   PubMedGoogle Scholar
• Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 2014; 15(8):707-16; PMID:25045879; http://dx.doi.org/10.1038/ni.2939
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99(3):754-8; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754
   PubMed Web of Science ®Google Scholar
• Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 2012; 97(6):937-42; PMID:22271896; http://dx.doi.org/10.3324/haematol.2011.050419
   PubMed Web of Science ®Google Scholar
• Rascu A, Repp R, Westerdaal NA, Kalden JR, van de Winkel JG. Clinical relevance of Fc gamma receptor polymorphisms. Ann NY Acad Sci 1997; 815:282-95; PMID:9186665; http://dx.doi.org/10.1111/j.1749-6632.1997.tb52070.x
   PubMed Web of Science ®Google Scholar
• Terszowski G, Klein C, Stern M. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. J Immunol 2014; 192(12):5618-24; PMID:24795454; http://dx.doi.org/10.4049/jimmunol.1400288
   PubMed Web of Science ®Google Scholar
• Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013; 12(10):2031-42; PMID:23873847; http://dx.doi.org/10.1158/1535-7163.MCT-12-1182
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Valiante N. Receptors for the Fc fragment of IgG on natural killer cells. Nat Immun 1993; 12(4–5):218-34; PMID:8257828
   PubMedGoogle Scholar
• Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013; 31:227-58; PMID:23516982; http://dx.doi.org/10.1146/annurev-immunol-020711-075005
   PubMed Web of Science ®Google Scholar
• Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: “l'union fait la force”. Blood 2005; 106(7):2252-8; PMID:15933055; http://dx.doi.org/10.1182/blood-2005-03-1154
   PubMed Web of Science ®Google Scholar
• Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004; 5(12):1260-5; PMID:15531883; http://dx.doi.org/10.1038/ni1138
   PubMed Web of Science ®Google Scholar
• Crouse J, Xu HC, Lang PA, Oxenius A. NK cells regulating T cell responses: mechanisms and outcome. Trends Immunol 2015; 36(1):49-58; PMID:25432489; http://dx.doi.org/10.1016/j.it.2014.11.001
   PubMed Web of Science ®Google Scholar
• Letourneur O, Kennedy IC, Brini AT, Ortaldo JR, O'Shea JJ, Kinet JP. Characterization of the family of dimers associated with Fc receptors (Fc epsilon RI and Fc gamma RIII). J Immunol 1991; 147(8):2652-6; PMID:1833456
   PubMed Web of Science ®Google Scholar
• Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol 2014; 92(3):221-9; PMID:24366519; http://dx.doi.org/10.1038/icb.2013.98
   PubMed Web of Science ®Google Scholar
• Capuano C, Romanelli M, Pighi C, Cimino G, Rago A, Molfetta R, Paolini R, Santoni A, Galandrini R. Anti-CD20 therapy acts via FcγRIIIA to diminish responsiveness of human natural killer cells. Cancer Res 2015; 75(19):4097-108; PMID:26229120; http://dx.doi.org/10.1158/0008-5472.CAN-15-0781
   PubMed Web of Science ®Google Scholar
• Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010; 115(11):2167-76; PMID:19965656; http://dx.doi.org/10.1182/blood-2009-08-238469
   PubMed Web of Science ®Google Scholar
• Grier JT, Forbes LR, Monaco-Shawver L, Oshinsky J, Atkinson TP, Moody C, Pandey R, Campbell KS, Orange JS. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest 2012; 122(10):3769-80; PMID:23006327; http://dx.doi.org/10.1172/JCI64837
   PubMed Web of Science ®Google Scholar
• Böttcher S, Ritgen M, Brüggemann M, Raff T, Lüschen S, Humpe A, Kneba M, Pott C. Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism. J Immunol Methods 2005; 306(1–2):128-36; PMID:16181633; http://dx.doi.org/10.1016/j.jim.2005.08.004
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D, Ravagnani V et al. The 158 VV Fcgamma receptor 3° genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis 2014; 73(4):716-21; PMID:23505228; http://dx.doi.org/10.1136/annrheumdis-2012-202435
   PubMed Web of Science ®Google Scholar
• Leppers-van de Straat FG, van der Pol WL, Jansen MD, Sugita N, Yoshie H, Kobayashi T, van de Winkel JG. A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. J Immunol Methods 2000; 242(1–2):127-32; PMID:10986395; http://dx.doi.org/10.1016/S0022-1759(00)00240-4
   PubMed Web of Science ®Google Scholar
• Paolini R, Molfetta R, Piccoli M, Frati L, Santoni A. Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement. Proc Natl Acad Sci USA 2001; 98(17):9611-6; PMID:11493682; http://dx.doi.org/10.1073/pnas.161298098
   PubMed Web of Science ®Google Scholar
• Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006; 107(1):159-66; PMID:16150947; http://dx.doi.org/10.1182/blood-2005-04-1351
   PubMed Web of Science ®Google Scholar
• Rajasekaran K, Kumar P, Schuldt KM, Peterson EJ, Vanhaesebroeck B, Dixit V, Thakar MS, Malarkannan S. Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells. Nat Immunol 2013; 14(11):1127-36; PMID:24036998; http://dx.doi.org/10.1038/ni.2708
   PubMed Web of Science ®Google Scholar
• Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M, Scott JM, Kamimura Y, Lanier LL, Kim S. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 2015; 42(3):431-42; PMID:25786175; http://dx.doi.org/10.1016/j.immuni.2015.02.013
   PubMed Web of Science ®Google Scholar
• Joyce MG, Tran P, Zhuravleva MA, Jaw J, Colonna M, Sun PD. Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site. Proc Natl Acad Sci USA 2011; 108(15):6223-8; PMID:21444796; http://dx.doi.org/10.1073/pnas.1100622108
   PubMed Web of Science ®Google Scholar
• Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, Fingerle-Rowson G, Wassner-Fritsch E, Gribben JG, Hallek M et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood 2015; 126(24):2646-9; PMID:26447188; http://dx.doi.org/10.1182/blood-2015-09-670802
   PubMed Web of Science ®Google Scholar
• Cox MC, Battella S, La Scaleia R, Pelliccia S, Di Napoli A, Porzia A, Cecere F, Alma E, Zingoni A, Mainiero F et al. Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. Oncoimmunology 2015; 4(3):e990773; PMID:25949906; http://dx.doi.org/10.4161/2162402X.2014.990773
   PubMed Web of Science ®Google Scholar
• Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011; 118(12):3347-9; PMID:21768303; http://dx.doi.org/10.1182/blood-2011-05-351411
   PubMed Web of Science ®Google Scholar
• Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 2005; 304(1–2):88-99; PMID:16109421; http://dx.doi.org/10.1016/j.jim.2005.06.018
   PubMed Web of Science ®Google Scholar
• Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, Luo X, Cooley S, Verneris M, Walcheck B et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013; 121(18):3599-608; PMID:23487023; http://dx.doi.org/10.1182/blood-2012-04-425397
   PubMed Web of Science ®Google Scholar
• Quatrini L, Molfetta R, Zitti B, Peruzzi G, Fionda C, Capuano C, Galandrini R, Cippitelli M, Santoni A, Paolini R. Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells. Sci Signal 2015; 8(400):ra108; PMID:26508790; http://dx.doi.org/10.1126/scisignal.aab2724
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. Blood 2015; 125(5):762-6; PMID:25498911; http://dx.doi.org/10.1182/blood-2014-10-569244
   PubMed Web of Science ®Google Scholar
• Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD, Han H, Chiang SC, Foley B, Mattsson K et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 2015; 42(3):443-56; PMID:25786176; http://dx.doi.org/10.1016/j.immuni.2015.02.008
   PubMed Web of Science ®Google Scholar
• Zhang T, Scott JM, Hwang I, Kim S. Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRγ deficiency. J Immunol 2013; 190(4):1402-6; PMID:23345329; http://dx.doi.org/10.4049/jimmunol.1203034
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol 2016; 16(2):112-23; PMID:26806484; http://dx.doi.org/10.1038/nri.2015.9
   PubMed Web of Science ®Google Scholar
• Galandrini R, Palmieri G, Paolini R, Piccoli M, Frati L, Santoni A. Selective binding of shc-SH2 domain to tyrosine-phosphorylated zeta but not gamma-chain upon CD16 ligation on human NK cells. J Immunol 1997; 159(8):3767-73; PMID:9378963
   PubMed Web of Science ®Google Scholar
• Negishi I, Motoyama N, Nakayama K, Nakayama K, Senju S, Hatakeyama S, Zhang Q, Chan AC, Loh DY. Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature 1995; 376(6539):435-8; PMID:7630421; http://dx.doi.org/10.1038/376435a0
   PubMed Web of Science ®Google Scholar
• Hesslein DG, Palacios EH, Sun JC, Beilke JN, Watson SR, Weiss A, Lanier LL. Differential requirements for CD45 in NK-cell function reveal distinct roles for Syk-family kinases. Blood 2011; 117(11):3087-95; PMID:21245479; http://dx.doi.org/10.1182/blood-2010-06-292219
   PubMed Web of Science ®Google Scholar
• Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells – enhancement by therapeutic antibodies. PLoS One 2007; 2(3):e326; PMID:17389917; http://dx.doi.org/10.1371/journal.pone.0000326
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Ravetch JV. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 2015; 161(5):1035-45; PMID:25976835; http://dx.doi.org/10.1016/j.cell.2015.04.016
   PubMed Web of Science ®Google Scholar
• Abès R, Gélizé E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010; 116(6):926-34; PMID:20439625; http://dx.doi.org/10.1182/blood-2009-10-248609
   PubMed Web of Science ®Google Scholar
• Capuano C, Paolini R, Molfetta R, Frati L, Santoni A, Galandrini R. PIP2-dependent regulation of Munc13-4 endocytic recycling: impact on the cytolytic secretory pathway. Blood 2012; 119(10):2252-62; PMID:22271450; http://dx.doi.org/10.1182/blood-2010-12-324160
   PubMed Web of Science ®Google Scholar
• Molfetta R, Quatrini L, Capuano C, Gasparrini F, Zitti B, Zingoni A, Galandrini R, Santoni A, Paolini R. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells. Eur J Immunol 2014; 44(9):2761-70; PMID:24846123; http://dx.doi.org/10.1002/eji.201444512
   PubMed Web of Science ®Google Scholar